Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~24 mi. (Cremona, Italy, +153 more cities)
facility
UO Oncologia, ASST di Cremona - Istituti Ospitalieri - Ospedale di Cremona
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~26 mi. (Parma, Italy, +383 more cities)
facility
Azienda Ospedaliero Universitaria di Parma
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~26 mi. (Parma, Italy, +122 more cities)
facility
A.O.U. di Parma
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~26 mi. (Parma, Italy, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~39 mi. (Reggio nell'Emilia, Italy, +115 more cities)
facility
Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type